RSV D486N-mut. fusion protein inh.

oral antiviral clinical candidate

from lower barrier to atropisomerism of lead

Bioorg. Med. Chem., Oct. 31, 2020

Taisho Pharmaceutical, Saitama, JP

“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks